Cyclosporin and bronchial healing in canine lung transplantation.
Long-term bronchial anastomotic healing has been assessed in the canine lung transplant model with cyclosporin as the primary immunosuppressant. Early bronchial revascularization was achieved by wrapping an omental pedicle around the bronchial anastomosis. Ten dogs underwent left lung transplantation and six survived 100 days or more before being put to death. No significant bronchial complications occurred. Late bronchostenosis was not seen, despite four biopsy-proved rejection episodes in three of the dogs surviving past 100 days. Histologically, all anastomoses were well healed at autopsy. Cyclosporin was shown to be an effective immunosuppressant in this model and was associated with prolonged survival and low morbidity. Transplant lung function was assessed at 100 days by contralateral pulmonary artery ligation in five dogs and was satisfactory in the three animals that had not had rejection episodes. The findings support our belief that bronchial anastomotic complications after human lung transplantation are mainly related to the effects of immunosuppression with steroids and to the ischemia resulting from division of the bronchial circulation at the time of transplantation.
D000818:Animals; D001980:Bronchi / Q000473:pathology* / Q000601:surgery; D003524:Cyclosporins / Q000494:pharmacology*; D004285:Dogs; D006084:Graft Rejection / Q000187:drug effects; D008168:Lung / Q000473:pathology; D016040:Lung Transplantation; D009852:Omentum / Q000637:transplantation; D010496:Pericardium / Q000637:transplantation; D013524:Surgical Flaps; D014945:Wound Healing / Q000187:drug effects*
D003524:Cyclosporins